# Minghui Pharmaceutical

Source: https://onco.cc/companies/minghui-pharmaceutical/  
OnCo record `minghui-pharmaceutical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Minghui Pharmaceutical is a China-based biotechnology company that leads 9 cancer trials in OnCo, testing its MHB-series antibody-drug conjugates and the bispecific antibody MHB039A in prostate cancer and advanced solid tumours.

## Summary

Minghui Pharmaceutical is a Hangzhou-based biopharmaceutical company. The ClinicalTrials.gov registry lists it as lead sponsor of trials of its antibody-drug conjugates MHB009C, MHB036C, MHB042C, MHB046C, MHB048C and MHB088C and of the bispecific antibody MHB039A in advanced solid tumours. No company website could be verified, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 9 trials recorded in OnCo: NCT07326488 (phase 1/2, A Study of MHB009C in Patients With Advanced Solid Tumors), NCT07229599 (phase 1/2, A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Ca...), NCT07130383 (phase 2, A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Oth...), NCT06373406 (phase 1/2, A Study of MHB036C for Advanced Solid Tumor), NCT06345482 (phase 1/2, A Study of MHB039A for Advanced Solid Tumor), NCT07192107 (phase 1/2, A Study of MHB042C in Patients With Advanced Solid Tumors), NCT06985355 (phase 1/2, A Study of MHB046C Injection in Patients With Advanced Solid Tumors), NCT07192120 (phase 1/2, A Study of MHB048C in Patients With Advanced Solid Tumors) and NCT07126665 (phase 1/2, A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Minghui Pharmaceutical (Hangzhou) Ltd
- Tags: ctgov-sponsor
- HQ: Hangzhou
- Type: biotech

## Sources

- ClinicalTrials.gov: trials led by Minghui Pharmaceutical: https://clinicaltrials.gov/search?lead=Minghui%20Pharmaceutical%20(Hangzhou)%20Ltd

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Furmonertinib](https://onco.cc/drugs/furmonertinib/), [MHB036C](https://onco.cc/drugs/mhb036c/), [MHB039A](https://onco.cc/drugs/mhb039a/), [QLC5508](https://onco.cc/drugs/qlc5508/)
- trials: [A Study of MHB009C in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07326488/), [A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer](https://onco.cc/trials/nct07229599/), [A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07130383/), [A Study of MHB036C for Advanced Solid Tumor](https://onco.cc/trials/nct06373406/), [A Study of MHB039A for Advanced Solid Tumor](https://onco.cc/trials/nct06345482/), [A Study of MHB042C in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07192107/), [A Study of MHB046C Injection in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06985355/), [A Study of MHB048C in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07192120/), [A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07126665/)

---
JSON: https://onco.cc/api/v1/entities/minghui-pharmaceutical.json